OPSCC: elderly patients experience survival benefits from chemoradiotherapy

  • Oral Oncol

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Chemoradiotherapy (CRT) is associated with improved survival of patients aged 70+ years with oropharyngeal squamous cell carcinoma (OPSCC), regardless of HPV status, according to a review of the National Cancer Database.

Why this matters

  • The role of chemotherapy in elderly patients with OPSCC is not well understood.

Key results

  • CRT was associated with improved OS compared with radiotherapy alone in multivariate analysis (HR, 0.74; P<.001 style="list-style-type:circle;">
  • This result was confirmed in propensity score-matched analysis (P<.001>
  • In subgroup analysis, CRT was associated with improved OS in patients with HPV-positive status (HR, 0.80; P=.05 in multivariate analysis; P<.001 in propensity score-matched analysis and hpv-negative status p multivariate>
  • There was no significant interaction between HPV status and the effect of CRT on survival (P=.57).
  • Study design

    • 1965 patients aged 70+ years with locally advanced (cT1-2N1-3, cT3-4N0-3) OPSCC, 58% with HPV-positive status and 42% with HPV-negative status, were analyzed for associations between treatment modality (61.6% received CRT, 38.4% received radiotherapy alone) and survival.
    • Funding: None disclosed.

    Limitations

    • Retrospective analysis of large database.